Skip to main content

Diabetes and Medication Possession Ratio for Statin Therapy

CBE ID
0547
Project
NVCS for Medication Management
Endorsed
New or Maintenance
Maintenance
Endorsement and Maintenance (E&M) Cycle
Full Year 2008
Is Under Review
No
Measure Description

Medication Possession Ratio (MPR) for statin therapy in diabetic individuals over 18 years of age

  • Measure Type
    Process
    Electronic Clinical Quality Measure (eCQM)
    No
    Level Of Analysis
    Clinicians: Group
    Clinicians: Individual
    Other
    Care Setting
    Ambulatory Care: Clinic
    Other Care Setting (Please specify)
    Numerator

    The sum of the days supply that fall within the measurement window for a statin fill for each patient in the denominator. Time Window: At any time during the measurement period (12 consecutive months)
    MPR Numerator:
    1. New users: For patients with no prescriptions in the 180 days prior to the measurement period, sum of:

    Days’ supply of all medications from the first prescription until the end of the measurement period.

    **Remove the days’ supply that extend past the end of the measurement period.

    2. Continuous users: For patients with 1 or more prescriptions in the 180 days prior to the measurement period, sum of:

    Days’ supply of all medications in the measurement period

    **Remove the days supply that extends past the end of the measurement period and add days supply from the previous period that apply to the current period

    Denominator

    Patients 18 - 85 years of age with diabetes mellitus and at least one Part D claim for a statin.
    MPR Denominator:
    1. New users: Number of days from the first prescription to the end of measurement period.
    2. Continuous users: Number of days from the beginning to the end of the measurement period.


    Time window: Anytime during the measurement period (12 consecutive months)

    Exclusions

    • Patients who died during the measurement period.
    • Patients who are actively enrolled in multiple plans concurrently as of the end of the measurement period.
    • Patients with a diagnosis of polycystic ovaries who do not have a face-to-face visit with a diagnosis of diabetes in any setting during the measurement period (if medical claims (Part A/B data) are available).
    • Patients with a diagnosis of gestational diabetes or steroid-induced diabetes who do not have a face-to-face visit with a diagnosis of diabetes in any setting during the measurement period (if medical claims (Part A/B data) are available).

    Testing Data Sources
    Electronic administrative data/claims
    Pharmacy data
  • Most Recent Endorsement Activity
    Measure Retired and Endorsement Removed NVCS for Medication Management 2008
    Initial Endorsement
    Endorsement Status
    Endorsement Removed
    Last Updated
    Removal Date